Credo Diagnostics Biomedical VitaPCR™ SARS-CoV-2 Assay Garners CE Mark
Credo Diagnostics Biomedical Pte. Ltd. announced today that it has obtained the CE Mark for its SARS-CoV-2 Assay. The rapid point-of-care molecular test for the novel Coronavirus COVID-19 is now commercially available in markets recognizing the designation. Leveraging its real-time PCR point-of-care platform VitaPCR™, the test allows the detection of SARS-CoV-2 in 20 minutes with […]
